3C-DFM

3C-DFM
Clinical data
Other names3C-Difluoromescaline; α-Methyldifluoromescaline; 4-(2,2-Difluoromethoxy)-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-(2,2-difluoromethoxy)amphetamine; 4-Difluoromethoxy-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-difluoromethoxyamphetamine
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • 1-[4-(difluoromethoxy)-3,5-dimethoxyphenyl]propan-2-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H17F2NO3
Molar mass261.269 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C(C(=C1)OC)OC(F)F)OC)N
  • InChI=1S/C12H17F2NO3/c1-7(15)4-8-5-9(16-2)11(18-12(13)14)10(6-8)17-3/h5-7,12H,4,15H2,1-3H3
  • Key:BQVYKMZBEBFRIG-UHFFFAOYSA-N

3C-DFM, also known as 4-(2,2-difluoromethoxy)-3,5-dimethoxyamphetamine or as or as α-methyldifluoromescaline (3C-difluoromescaline), is a serotonin receptor modulator of the phenethylamine and 3C families.[1][2][3] It is the amphetamine (α-methyl) derivative of the psychedelic drug difluoromescaline (DFM).[1][2][3] The properties and effects of 3C-DFM in humans are unknown.[1][2] The drug shows affinity for the serotonin 5-HT2 receptors and is known to act as an agonist of the serotonin 5-HT2A and 5-HT2B receptors.[3][2] 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012.[2][1][3] It is a controlled substance in Ukraine.[4] The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.[5]

See also

References

  1. ^ a b c d Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 736–737. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. ^ a b c d e Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
  3. ^ a b c d Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  4. ^ "4-Дифторметокси-3,5-диметоксиамфетамин". АИПСИН (in Russian). Retrieved 6 January 2026.
  5. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.